Predictors of Severe COVID-19 Outcomes (PRESCO)

V

Verily Life Sciences

Status

Unknown

Conditions

COVID-19
Acute Respiratory Distress Syndrome

Study type

Observational

Funder types

Industry

Identifiers

NCT04388813
102293

Details and patient eligibility

About

This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.

Enrollment

494 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participant or legally authorized representative willing and able to provide informed consent
  • Receiving care at a participating site
  • Age 18 years old or older
  • U.S. Resident
  • Confirmed positive for COVID-19
  • Willing and able to comply with all study procedures

Exclusion criteria

Self reported pregnancy

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems